

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Toshihiro TANAKA et al.

Confirmation No. : 1079

Appl. No. : 10/523,723

Group Art Unit : 1634

I.A. Filed : August 8, 2003

Examiner : Katherine Salmon

For : METHOD OF JUDGING INFLAMMATORY DISEASE

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98,

Applicants hereby submit this Supplemental Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.

Applicants direct the Examiner's attention to the documents listed in the attached PTO-1449 Form, including the documents cited in the Office Action for Japanese Application No. 2004-527375, which is a corresponding application of the above-referenced application. A copy of the Japanese Office Action is submitted herewith.

Applicants note that a copy of Messer et al., Journal of Exp. Med., (1991), Vol. 173, pages 209-219 is not included, as this document was submitted in the Information Disclosure Statement filed on March 1, 2006.


Copies of the documents listed in the PTO-1449 Form are enclosed together with a completed copy of the PTO-1449 Form. Accordingly, the Examiner is requested to consider

these documents and to indicate such consideration by returning a signed copy of the PTO-1449 Form with the next official communication. If additional copies of any other documents are needed, the Examiner is requested to contact the undersigned.

Applicants note that this Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Applicants hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application more than three months prior to the filing of this Information Disclosure Statement 37 C.F.R. § 1.97 (e)(1). Thus, no fee is believed necessary to ensure consideration of the submitted material. If a fee is required for any reason, then this should be considered express authorization to charge any necessary fee for consideration of this Information Disclosure Statement to Deposit Account No. 19-0089.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully Submitted,
Toshihiro TANAKA et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

October 20, 2009
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191